BioCentury
ARTICLE | Strategy

A near death experience

February 20, 2006 8:00 AM UTC

Four years ago, with barely E1 million in the bank, Pharming Group N.V. was forced into receivership, having bitten off more than it could chew trying to develop alpha glucosidase to treat Pompe's disease in a joint venture with Genzyme Corp.

Today, Pharming (Euronext: PHARM, Leiden, the Netherlands) has about four years of cash, its recombinant human C1 esterase inihibitor (rhC1INH) is in Phase III trials to treat hereditary angioedema, and its recombinant human lactoferrin is poised to enter the market as a food supplement. ...